NEW YORK, NY--(Marketwire - Nov 9, 2011) - Shares throughout the biotechnology sector have been exceptionally volatile of late as developments regarding government approvals, litigation and shockingly disappointing earnings elicit large movements in stock prices. The Bedford Report examines the outlook for companies in the healthcare sector and provides investment research on Rexahn Pharmaceuticals, Inc. (NYSE Amex: [ RNN ]) and Elite Pharmaceuticals, Inc. (OTCBB: [ ELTP ]). Access to the full company reports can be found at:

[ www.bedfordreport.com/RNN ]

[ www.bedfordreport.com/ELTP ]

Some lawmakers in Washington have been arguing that the FDA's tougher safety stance has slowed down the pace of drug approvals and hurting the pharmaceutical and biotech industry. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.

Janet Woodcock, the head of the FDA's drug division, defended the FDA's role, saying challenges being faced by the biotech and pharmaceutical industry are related to high failure rates of drugs in the development process rather than FDA regulations.

The Bedford Report releases market research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.bedfordreport.com ] and get exclusive access to our numerous analyst reports and industry newsletters.

Elite Pharmaceuticals is a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products, using technology. Earlier this Fall, Elite Pharmaceuticals and ECR Pharmaceuticals ("ECR"), a wholly owned subsidiary of Hi-Tech Pharmacal (Hi-Tech), announced the launch of Lodrane D®. Lodrane D® is an immediate release formulation of brompheniramine maleate and pseudoephedrine HCl, an effective, low-sedating antihistamine combined with a decongestant.

Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin, Serdaxin, and Zoraxel.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at [ http://www.bedfordreport.com/disclaimer ]